Find a Clinical Trial

Karyopharm is committed to developing novel treatment options to patients in need. Search here for ongoing clinical trials evaluating Karyopharm’s investigational medicines. For more information about our clinical trials, please reach out to clinicaltrials@karyopharm.com

Karyopharm-Sponsored Trials Investigator-Sponsored Trials

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Primary Condition
Endometrial Cancer
Sponsor
Karyopharm Therapeutics Inc
Status
Recruiting
Drug
Selinexor
Matching Placebo for selinexor
Phase
Phase3
Age Group
18 Years+
Primary Condition
Endometrial Cancer

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.
Primary Condition
Endometrial Cancer
Sponsor
Karyopharm Therapeutics Inc
Status
Active Not Recruiting
Drug
Selinexor
Phase
Phase3
Age Group
18 Years+
Primary Condition
Endometrial Cancer